MSH2 is required for cell proliferation, cell cycle control and cell invasiveness in colorectal cancer cells by Kai Shen et al.
   
 
© The Author(s) 2012. This article is published with open access at Springerlink.com csb.scichina.com   www.springer.com/scp 
                      
†These authors contributed equally to this work. 
*Corresponding author (email: dr.wangshan@yahoo.com.cn) 
Article 
SPECIAL TOPICS:  
Preclinical Medicine July 2012  Vol.57  No.20: 25802585 
 doi: 10.1007/s11434-012-5258-0 
MSH2 is required for cell proliferation, cell cycle control and cell 
invasiveness in colorectal cancer cells 
SHEN Kai†, YE YingJiang†, JIANG KeWei, LIANG Bin, YANG XiaoDong & WANG Shan* 
Department of Gastroenterological Surgery, Surgical Oncology Laboratory, Peking University People’s Hospital, Beijing 100044, China 
Received January 5, 2012; accepted April 10, 2012 
 
We have investigated the role of MSH2, a mismatch repair gene in cell proliferation, cell cycle control and cell invasiveness in the 
SW480 human colorectal cancer cell line. RNAi-mediated inhibition of MSH2 expression was achieved using MSH2 shRNA len-
tiviral expression vectors. Effective knockdown of endogenous MSH2 expression was determined by real-time PCR analysis. The 
most efficient MSH2 knockdown vector was selected for subsequent studies using SW480 cells. Endogenous MSH2 mRNA levels 
decreased after lentiviral delivery of the MSH2-RNAi, indicating efficient silencing of MSH2 expression in SW480 cells. Cell 
proliferation, cell cycle progression and cell invasiveness were quantified by MTT assays, flow cytometry and transwell assays, 
respectively. RNAi-mediated inhibition of MSH2 expression in SW480 cells resulted in decreased cell proliferation, cell cycle 
arrest at the G0/G1 phase and decreased cell invasiveness. Taken together, these results provide evidence that MSH2 stimulates 
cell proliferation, promotes cell cycle progression and positively regulates cell invasiveness. 
colorectal cancer, hereditary nonpolyposis, RNAi, MSH2 
 
Citation:  Shen K, Ye Y J, Jiang K W, et al. MSH2 is required for cell proliferation, cell cycle control and cell invasiveness in colorectal cancer cells. Chin Sci Bull, 




Colorectal carcinoma (CRC) is one of the most common 
malignant tumors of the gut, and it has been associated with 
increasing morbidity in China in recent years (http://seer. 
cancer.gov). Hereditary nonpolyposis colorectal carcinoma 
(HNPCC, Lynch syndrome) is the most common hereditary 
form of CRC, and it is believed to account for between 
5%–10% of the total CRC burden [1]. HNPCC is character-
ized genetically by pathogenic germline mutations in DNA 
mismatch repair (MMR) genes, most often in the MLH1 and 
MSH2 genes [2]. Recent studies have shown that MSH2 
plays an important role, not only in mismatch repair, but also 
in cell proliferation, apoptosis and cell cycle control [3].  
MSH2 is a component of the highly conserved post-  
replicative DNA MMR system. DNA MMR proteins con-
tribute to DNA replication fidelity by removing insertion or 
deletion loops that result from template primer slippage at 
repetitive DNA sequences, and by correcting single base 
mismatches that escape polymerase proofreading, thereby 
preventing the accumulation of spontaneous mutations and 
ensuring the integrity and stability of the genome [4,5]. 
MSH2 has been shown to play an important role in the 
regulation of cell proliferation. Srivastava et al. [6] reported 
that MSH2 protein levels were significantly higher in 28 
glioblastoma multiforme samples relative to 27 unpaired 
astrocytoma samples; in contrast, no such differences in 
MLH1 levels were observed. 
Experimental evidence has shown a role for MMR genes 
in the regulation of apoptosis. Zhang et al. [7] found that 
over-expression of MSH2 or MLH1, but not MSH3, MSH6 
or PMS2, induced apoptosis in either repair-proficient or 
repair-deficient cells, suggesting that the mismatch repair 
proteins MSH2 and MLH1 may be components of a path-
way that influences apoptosis. 
DNA damage can lead to genomic instability. Genomic 
instability is often inhibited following cell cycle arrest. G2 
and S phase checkpoints and many associated proteins, in-
cluding ATM, ATR, p53, p73, Chk1 and Chk2 [8–10] have 
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shown important roles in the regulation of genomic stability.  
In the current study, we carried out MSH2 RNAi experi-
ments to investigate the role of MSH2 in colon cancer cell 
proliferation, cell cycle regulation and cell invasiveness. 
1  Materials and methods 
1.1  Cell culture 
The SW480 cell line was maintained in RPMI-1640 medi-
um supplemented with 10% fetal bovine serum (FBS), 100 
IU/mL penicillin and 100 g/mL streptomycin. SW480 
cells were infected with different lentiviral strains at an 
MOI of approximately 10–50 for 3–5 d, lysed and subjected 
to RT-PCR. All cell culture reagents were from Gibco. 
1.2  MSH2 RNAi lentivirus generation 
The full-length human MSH2 mRNA sequence was submit-
ted to the siRNA design center of Shanghai GeneChem Co. 
for the generation of four oligo sequences against MSH2. 
The MSH2 RNAi target sequences included:  
#1: 5′-AACCTTCATTTGATCCTAA-3′, starting at the 
+1479 site in the mature MSH2 mRNA; 
#2: 5′-CTTGAGGAGTTTCAGTATA-3′, starting at the 
+2618 site in the mature MSH2 mRNA; 
#3: 5′-AGGTGTCTGTGATCAAAGT-3′, starting at the 
+2524 site in the mature MSH2 mRNA; 
#4: 5′-GAAGATGCAGTCAACATTA-3′, starting at the 
+1537 site in the mature MSH2 mRNA; and  
non-target control: 5′-TTCTCCGAACGTGTCACGT-3′. 
For the shRNA-expressing lentiviral vector, RNAi stem- 
loop DNA oligos were designed and synthesized by Shang-
hai GeneChem Co. (Table 1). The oligos were annealed and 
cloned into the lentivirus-based RNAi vector, pGCL-GFP 
(Addgene, Shanghai GeneChem Company, Shanghai, Chi-
na), and a non-targeting stem-loop DNA was cloned into 
pGCL-GFP to generate the negative control lentiviral vec-
tors. The lentiviral infecting particles were prepared as de-
scribed previously [11]. Cells were infected with the 
MSH2-RNAi-lentivirus or with negative control virus when 
they were 30%–40% confluent, and were examined 2–8 d 
later. Briefly, 293T cells were co-transfected with the 
pGCL-GFP RNAi vector and packaging vectors, and the 
resulting supernatant was collected after 48 h. The virus was 
recovered after ultracentrifugation for 3.5 h at 25000 r/min 
in a Beckman SW28 rotor and resuspended in phosphate-  
Table 1  DNA sequences of the MSH2 shRNAs  
Marker Gene TargetSeq 
1#-RNAi-LV MSH2 AACCTTCATTTGATCCTAA 
2#-RNAi-LV MSH2 CTTGAGGAGTTTCAGTATA 
3#-RNAi-LV MSH2 AGGTGTCTGTGATCAAAGT 
4#-RNAi-LV MSH2 GAAGATGCAGTCAACATTA 
NC-RNAi-LV  TTCTCCGAACGTGTCACGT 
buffered saline (15–200 L). Titers were determined by 
infecting 293T cells with serial dilutions of concentrated 
lentivirus. We determined EGFP expression in infected cells 
by flow cytometry (FACSCalibur, BD, USA) at 96 h post- 
infection; in a typical preparation, the titer was approxi-
mately 1–2×108 infectious units (IFU) per mL. 
1.3  RT-PCR reactions 
A TRIZOL Reagent kit (Invitrogen) was used to isolate 
mRNA from infected cells. First-strand synthesis and PCR 
reactions were performed using M-MLV reverse transcrip-
tase and Taq polymerase (Promega), respectively, according 
to the manufacturer’s instructions. The actin primer set in-
cluded the hActin-F primer (5′-GTGGACATCCGCAAA- 
GAC-3′) and the hActin-R primer (5′-AAAGGGTGTAAC- 
GCAACTA-3′). The human MSH2 primer set included the 
MSH2-F primer (5′-GCCATGTGAGTCAGCAGAAG-3′) 
and the MSH2-R primer (5′-CCCAAATCCATCGTAGG- 
TAGAAG-3′). Quantification of the RT-PCR results was 
conducted using BioRadQ5 software, and statistical anal-
yses were performed using a one-way ANOVA analysis. 
Differences with a P value of < 0.05 were considered statis-
tically significant. Experiments with multiple experimental 
conditions were repeated at least three times.  
1.4  Cell survival assay 
SW480 cells were divided into three groups. Control group: 
normal SW480 cells; NC-RNAi-LV group: SW480 cells 
infected by the lentivirus without the specific interference 
RNA; MSH2-RNAi-LV group: SW480 cells infected by the 
lentivirus with the specific interference RNA. Cell survival 
and proliferation were determined using the 3-(4,5-dime- 
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
colorimetric assay. Cells were plated in a 24-well plate at a 
density of 50000 cells/well and incubated overnight in the 
presence of 10% FBS. Cells were infected with different 
MSH2-RNAi lentiviruses for different periods of time. To 
examine cell survival/proliferation, a one-tenth volume of 
MTT (5 mg/mL in PBS, Sigma) was added to each well, 
and the plate was maintained for an additional 3 h in the 
incubator. After removing the medium, the insoluble me-
tabolized MTT substrate was dissolved in acid-isopro- pa-
nol (100 µL/well, 0.07 mol/L HCl-isopropanol). The plates 
were rocked gently, and the absorbance of the supernatant 
was measured spectrophotometrically (Thermo Labsystems, 
MK3, USA) at 490 nm. The values obtained were propor-
tional to the number of viable cells, and the results are ex-
pressed as the mean ± SEM values (n > 3). Cell survival 
was also estimated using flow cytometry. Propidium iodide 
(PI, Sigma) was added to a final concentration of 50 μg/mL 
30 min before analyzing the cell cycle profile by flow cy-
tometry. The percentages of cells in different cell cycle 
phases are expressed as the mean ± SEM (n > 3). Cell inva-
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sion was measured by an inclined test using polycarbonate 
filters incorporated into modified Transwell chambers. Cells 
stained with crystal violet (purple colored cells) indicated 
the number of cells that had migrated across the membrane. 
The migration rate of SW480 cells was calculated by the 
ratio of migrated cells/total cells (the migrated cells were 
dissolved in 10% acetic acid and measured spectrophoto-
metrically at 570 nm). 
1.5  Statistical analyses 
One-way ANOVA analysis was used to evaluate the differ-
ences among the three groups: control, NC-RNAi-LV and 
MSH2-RNAi-LV in respects of cell proliferation, cell cycle 
control and cell invasiveness. SPSS Version 13.0 software 
(SPSS, Chicago, IL, USA) was used for all statistical anal-
yses. P < 0.05 was considered to be statistically significant. 
2  Results 
2.1  Efficient knockdown of MSH2 expression in 
SW480 cells 
Four pairs of RNAi targeting sequences were synthesized  
and inserted into the lentiviral expression vector pGCL-GFP, 
as shown in Figure 1(a) and Table 1. Initial experiments to 
screen the RNAi target sequences were performed using 
293T cells, which were infected with control (NC-RNAi- 
LV) or one of the four MSH2-RNAi lentiviral particles. 
Infected 293T cells were allowed to grow for 4 d before 
total RNA was extracted. Percentage infection was moni-
tored by light microscopic observation of the ratio of EGFP- 
positive cells relative to the total number of cells; in these 
experiments, more than 80% of cells were infected by lenti-
virus (Figure 1(b), left panel). Infection of 293T cells with 
lentiviruses expressing MSH2-RNAi #2, #3 or #4 led to ef-
fective knockdown of endogenous MSH2 expression, as de-
termined by RT-PCR analysis. MSH2-RNAi #3 showed the 
most efficient MSH2 knockdown (the knockdown efficiency 
was 55%), and was selected for subsequent studies using 
SW480 cells (Figure 1(b), right panel). Taken together, these 
data suggested that the lentiviral vector-based MSH2-RNAi 
effectively inhibited endogenous MSH2 expression.  
As the MSH2-RNAi #3 vector most effectively inhibited 
MSH2 expression in 293T cells, we carried out experiments 
to determine whether it also silenced endogenous MSH2 
expression in SW480 cells. We infected SW480 cells with  
 
 
Figure 1  Summary of MSH2 RNAi experiments. (a) Generation of a lentiviral vector for expression of MSH2 shRNAs. The pGCL vector was engineered 
by introducing the mouse U6 promoter upstream of a PCMV-EGFP expression cassette to generate a vector that simultaneously produces shRNA and the 
EGFP reporter gene. CMV, cytomegalovirus promoter; WRE, woodchuck hepatitis virus response element. (b) Specific degradation of MSH2 mRNA in-
duced by different MSH2-RNAi lentiviral vectors. EGFP expression levels in infected 293T cells (left). Bar graphs represent average MSH2 expression 
levels (%) relative to a vehicle control (VC) (right). Error bars represent the SEM. All samples were normalized to actin expression. (c) Functional silencing 
of MSH2 expression in SW480 cells infected with an MSH2-RNAi lentiviral vector and control vectors. EGFP expression levels in SW480 cells infected 
with MSH2-RNAi lentiviral and control vectors (left). Bar graphs represent average MSH2 expression levels (%) relative to a VC (right). Error bars repre-
sent the SEM. All samples were normalized to actin expression. 
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either NC-RNAi-LV or MSH2-RNAi #3 lentivirus (MSH2- 
RNAi-LV). Total RNA was extracted from SW480 cells at 
4 d post-infection, and was subjected to RT-PCR analysis to 
evaluate endogenous MSH2 mRNA levels. Endogenous 
MSH2 mRNA expression decreased after lentiviral delivery 
of the MSH2-RNAi (Figure 1(c)) (the knockdown efficien-
cy was 80%), showing efficient silencing of MSH2 expres-
sion in SW480 cells. 
2.2  RNAi-mediated silencing of MSH2 expression in 
colon cancer cells led to decreased cell proliferation, a 
G0/G1 cell cycle arrest and reduced cell invasiveness 
To determine whether inhibition of MSH2 expression in 
colon cancer cells may influence tumor cell proliferation, 
we performed MTT assays to study cell proliferation. 
SW480 cell proliferation rates began to decrease 72 h after 
RNAi-mediated MSH2 silencing. At both 72 and 120 h after 
RNAi-mediated MSH2 silencing, we noted significantly 
lower rates of cell proliferation relative to control cells 
(Figure 2(a), Table 2). This result showed that the inhibition 
of MSH2 expression in colon cancer cells led to decreased 
cell proliferation, and provided evidence that MSH2 may 
play an important role in the regulation of colon cancer cell 
proliferation in vivo. 
We also used flow cytometry to study cell cycle progres-
sion following RNAi-mediated inhibition of MSH2 expres-
sion. Five days after RNAi-mediated MSH2 silencing, 
SW480 cells were stained with PI and analyzed by flow cy-
tometry. The results of these experiments showed that de-
creased MSH2 expression led to cell cycle arrest in the G0/G1 
phase (Figure 2(b), Table 3). These data suggested that 
MSH2 may play an important role in the G1/S checkpoint.  
Table 2  Cell proliferation in colon cancer cells after RNAi-mediated 
silencing of MSH2 expression (MTT assays)a)  
Day Control (A) NC-RNAi-LV (A) MSH2-RNAi-LV (A) P 
1 0.056±0.003 0.055±0.003 0.062±0.009 0.329 
2 0.173±0.005 0.149±0.002 0.178±0.009 0.343 
3 0.444±0.026 0.434±0.028 0.353±0.018 0.007 
4 0.755±0.125 0.695±0.032 0.588±0.037 0.095 
5 0.790±0.072 0.784±0.035 0.654±0.039 0.030 
a) P < 0.05. 
 
 
Figure 2  RNAi-mediated inhibition of MSH2 expression in cultured SW480 cells induced decreased proliferation, G0/G1 phase arrest and decreased inva-
siveness. (a) Quantification of SW480 cell survival, as determined by MTT assays (n = 3; P < 0.05). Error bars represent the SEM. SW480 cell viability was 
reduced 48 h after infection with the MSH2-RNAi lentiviral vector. (b) G0/G1 cell cycle arrest 5 d after infection with the MSH2-RNAi lentiviral vector 
relative to uninfected control cells, as determined by flow cytometry (top). Data are shown as mean ± SEM. (c) Cell invasiveness was determined by 
transwell assays. Cells stained with crystal violet (purple) represent invasive cells. The transmembrane invasion rate of SW480 cells was calculated as the 
ratio of purple cells/total cells (measured spectrophotometrically at 570 nm).  
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Table 3  Cell survival in colon cancer cells after RNAi-mediated silenc-
ing of MSH2 expression (flow cytometry) a) 
 Control NC-RNAi-LV MSH2-RNAi-LV P 
G0/G1 (%) 20.92±4.89 29.33±2.28 48.49±2.18 0.000 
G2/M (%) 44.20±8.51 47.18±3.87 24.81±1.10 0.005 
S (%) 48.49±2.18 23.48±1.63 26.69±1.45 0.113 
a) P < 0.05. 
 
 
Transwell assays were carried out to determine the inva-
siveness of SW480 cells following RNAi-mediated inhibi-
tion of MSH2. Five days after RNAi-mediated MSH2 si-
lencing, SW480 cells exhibited decreased rates of cell inva-
siveness, as determined by the amount of transmembrane 
crystal violet (CV) staining, which was measured spectro-
photometrically (Figure 2(c), Table 4). The results of this 
experiment showed that decreased MSH2 expression was 
associated with decreased cell invasiveness, and suggested 
that MSH2 may positively regulate cell invasion. 
3  Discussion 
In the current study, a simulated HNPCC cell model was 
established by knocking down MSH2 expression in the co-
lon cancer cell line, SW480, using shRNA-mediated inter-
ference (RNAi). Van Oosten et al. [12] used MSH2–/– mice 
and derived keratinocytes to show that MSH2 plays a role in 
the generation of UVB-induced arrested cells: MSH2 defi-
ciency lowered the percentage of arrested cells both in vivo 
(40%–50%) and in vitro (30%–40%). UVB-induced apop-
tosis is reduced in MSH2-deficient cells, and correlates with 
decreased activation of p53, suggesting that MSH2 may act 
upstream of p53 to induce UVB-mediated apoptosis. Chang 
et al. [13] examined chemosensitivity and the cell cycle 
response to oxidative stress in several MMR-deficient 
(HCT116, SW48 and DLD1) and MMR-proficient (CaCo2, 
SW480 and HT29) colon cancer cell lines. RNAi-mediated 
gene silencing has been used in recent studies, for example 
Wei et al. [14] reported the silencing of STAT4 by siRNA 
in mouse lymphoma cell line (EL-4).  
MSH2 has been shown to play a role in cell proliferation. 
In our study, RNAi-mediated MSH2 silencing in SW480 
cells led to decreased cell proliferation. Srivastava et al. [6] 
reported significantly higher levels of MSH2 protein in 28 
glioblastoma multiforme samples relative to 27 unpaired 
astrocytoma samples; however no such difference in MLH1 
levels was observed. Bae-Jump et al. [15] reported rapamycin 
Table 4  Cell invasiveness of colon cancer cells after RNAi-mediated 











Transmembrane rate 0.737±0.018 0.712±0.037 0.630±0.045 0.023 
a) P < 0.05. 
increased cisplatin-induced apoptosis and stimulated ex-
pression of MSH2 and MSH6 in endometrial cancer cell 
lines, which showed that MSH2 correlated with cell prolif-
eration. In tissues with high proliferative activity, such as 
digestive mucosa and endometrium, an increase in MSH2 
protein levels may be required to protect cells from DNA 
replication errors [16].  
MSH2 binds to CHK1 and CHK2 both in vivo and in 
vitro [17]. ATM (ataxia-telangiectasia-mutated kinase), 
CHK1 and CHK2 have all been implicated in triggering the 
G2/M checkpoint response, and MMR genes are presumed 
to play a role in the G2/M cell cycle checkpoint [18]. Cam-
pregher et al. [19] used an in vitro co-culture model that 
mimicked intestinal inflammation in ulcerative colitis, in 
which the activated neutrophils caused an accumulation of 
target cells in G2/M, which was consistent with the installa-
tion of a DNA-damage checkpoint. Cells that did not ex-
press MSH2, p53 or p21waf1/cip1 failed to undergo the G2/M 
arrest. They provided molecular evidence for an MSH2- 
dependent G2/M checkpoint arrest and for the presence of 
replication errors. Following UV irradiation, p53 activates 
the transcription of the MMR gene, MSH2. Evidence sug-
gests that MSH2 and p53 may provide positive feedback 
regulation for the DNA damage response after UV irradia-
tion, and that MSH2 may also function in UV-induced G1 
arrest [20]. In our study, RNAi-mediated MSH2 silencing in 
SW480 cells led to a cell cycle arrest at the G0/G1 phase, 
providing evidence for a role of MSH2 in the G1/S check-
point. MSH2 plays an important role in cell cycle control. 
HNPCC patients, who often carry inactivating mutations 
in the MSH2 gene, have better survival rates than sporadic 
CRC patients [21]. Nijhuis et al. [22] found that the absence 
of MSH2 expression is associated with a high-risk profile in 
early stage cervical cancer. However, in our study, colon 
cancer cell invasiveness was decreased in cells subjected to 
RNAi-mediated inhibition of MSH2 expression. These 
findings provide insights into the molecular basis of the 
clinical features of HNPCC. Collectively, our results sug-
gest that MSH2 may serve as a potential therapeutic target 
for gene therapy-based approaches to colon cancer, thus 
establishing a basis for future clinical studies aimed at the 
treatment of CRC patients. 
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